WANY
HRMY icon

Wealthspire Advisors (New York)’s Harmony Biosciences HRMY Stock Holding History

Wealthspire Advisors (New York)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-147
Closed -$4.05K – 1853
2025
Q3 		$4.05K Buy
+147
New +$5.06K ﹤0.01% 2404

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealthspire Advisors (New York)'s HRMY Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 147 shares — an estimated $4.05K sold.

Wealthspire Advisors (New York) first reported a position in HRMY in Q3 2025 and held it in 1 quarter. The position peaked at $4.05K in Q3 2025. 325 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 147 Harmony Biosciences shares in Q4 2025, an estimated $4.05K.
  • Wealthspire Advisors (New York) first reported a position in Harmony Biosciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Harmony Biosciences position peaked at $4.05K in Q3 2025.
  • 325 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.